Vivos Therapeutics, Inc. - VVOS STOCK NEWS

Vivos Therapeutics (NASDAQ: VVOS) reported strong Q3 2024 financial results with revenue increasing 17% to $3.9 million compared to Q3 2023. Gross profit reached $2.3 million with margins improving to 60%. Operating expenses decreased by 8%, marking the ninth consecutive quarter of year-over-year reductions. The company achieved significant milestones including FDA clearance for treating moderate to severe OSA in children ages 6-17 and new AMA CPT codes for their devices effective January 2024. Patient treatments increased to over 47,000 worldwide, with more than 2,000 trained dentists. The company projects achieving positive cash flow from operations by mid-2025.

Vivos Therapeutics (NASDAQ: VVOS), a medical device company focused on sleep-related breathing disorders treatment, announced its plans to release Q3 2024 financial results after market close on November 14, 2024. The company will host a conference call at 5:00 PM ET on the same day to discuss results and recent developments. Investors can access the call via phone at (800) 717-1738 (US) or (646) 307-1865 (International). A replay will be available until November 29, 2024, and a live webcast can be accessed through the company's website.

Vivos Therapeutics (NASDAQ: VVOS) has announced that the American Medical Association (AMA) has issued new CPT® medical codes for all Vivos CARE oral medical devices, effective January 1, 2025. This development is expected to facilitate coverage and reimbursement by commercial medical insurance payers for the treatment of obstructive sleep apnea (OSA) in adults and children.

Vivos Chairman and CEO, Kirk Huntsman, stated that this approval will enable a larger number of patients to access their proprietary airway remodeling technology. The company believes this, along with recent regulatory approvals and their new alliance-based marketing and distribution model, will improve their position to drive revenue growth.

The AMA's CPT® 2025 code set includes 420 overall updates, with 270 new codes, 112 deletions, and 38 revisions. This approval follows Vivos' recent Medicare coverage approval and is seen as a major step towards making OSA treatment more accessible and affordable for patients nationwide, including children ages 6 to 17.

Vivos Therapeutics (NASDAQ: VVOS), a medical device company specializing in sleep-related breathing disorders treatments, has announced a $4.3 million registered direct offering of common stock. The offering involves the sale of 1,363,812 shares at $3.15 per share, priced at-the-market under Nasdaq rules. No warrants are being issued. The offering is expected to close around September 20, 2024, with H.C. Wainwright & Co. acting as the exclusive placement agent. Vivos intends to use the net proceeds for working capital and general corporate purposes. The offering is made pursuant to a previously filed and effective shelf registration statement.

Vivos Therapeutics (NASDAQ: VVOS) has received a groundbreaking FDA 510(k) clearance for its DNA appliance to treat moderate to severe obstructive sleep apnea (OSA) and snoring in children aged 6 to 17. This is believed to be the first such clearance for an oral medical device in pediatric OSA treatment. The approval is based on a multi-site clinical trial that showed significant improvements in OSA symptoms and airway volumes.

Key findings from the study include:

• 50% reduction in sleep-related breathing disorder symptoms
• 58% decrease in snoring
• 62.7% improvement in moderate and severe AHI measurements
• 40% increase in airway volumes

Vivos aims to disrupt the pediatric OSA market, estimated at 10.1 million U.S. children, with its non-invasive, safe, and effective treatment option.

Vivos Therapeutics (NASDAQ: VVOS) reported strong Q2 2024 financial results, with revenue increasing 19% both sequentially and year-over-year to $4.1 million. The company saw operating expenses decrease by 31%, marking eight consecutive quarters of year-over-year improvement. Gross profit rose to $2.7 million, with gross margin increasing to 65%. Vivos' cost-cutting initiatives led to a significant 57% reduction in operating loss. The company anticipates achieving positive cash flow in early 2025.

Key developments include receiving regulatory approvals for Medicare reimbursement of CARE oral devices, a strategic marketing alliance with a Colorado sleep center operator, and a $7.5 million equity investment from New Seneca Partners. Vivos also reported positive results from a marketing pilot for its new distribution model, with 79% of newly diagnosed OSA patients choosing Vivos' oral appliance therapy.

Vivos Therapeutics (NASDAQ: VVOS), a leading medical device company focusing on sleep-related breathing disorders, has announced the release of its second quarter 2024 financial results after market close on August 14, 2024. The company will host a conference call at 5:00 pm ET on the same day to discuss the results and provide updates on recent achievements and developments.

Investors can access the call by dialing (800) 717-1738 (US) or (646) 307-1865 (international). A replay will be available until August 28, 2024, accessible by dialing (844) 512-2921 (US) or (412) 317-6671 (international) with passcode 1157721. A live webcast and 30-day archive will be available on the company's investor relations website.

Vivos Therapeutics announced positive results from a 7-month, multi-site pilot of its new provider-based marketing and distribution model. Conducted in seven dental and one ENT office, the pilot involved 99 patients with diverse demographics. 79% of newly diagnosed adult OSA patients preferred Vivos' oral appliance therapy over CPAP, with Vivos' devices chosen 5 to 1 over traditional appliances. Pediatric patients with orofacial issues were also successfully treated. Vivos aims to drive revenue through collaborations with dentists and sleep specialists, expecting positive impacts on new cases, revenue growth, and gross profit.

Vivos Therapeutics (NASDAQ: VVOS) announced a $7.5 million private equity investment from Seneca Partners to support a new strategic alliance with sleep treatment centers in Colorado. The alliance aims to enhance revenue through a new marketing and distribution model for Vivos' OSA treatment devices, starting with two centers in July 2024. Vivos intends to expand this model nationally. The investment boosts Vivos' cash reserves and shareholders' equity. Seneca will also offer management advisory services. Key investment terms include the purchase of 3,220,266 shares and associated warrants, with an 'at the market' price of $2.329 per share.